Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer

Non-invasive radionuclide imaging of human epidermal growth factor receptor type 2 (HER2) expression in breast, gastroesophageal, and ovarian cancers may stratify patients for treatment using HER2-targeted therapeutics. Designed ankyrin repeat proteins (DARPins) are a promising type of targeting probe for radionuclide imaging. In clinical studies, the DARPin [99mTc]Tc-(HE)3-G3 labeled using a peptide-based chelator His-Glu-His-Glu-His-Glu ((HE)3), provided clear imaging of HER2 expressing breast cancer 2–4 h after injection. The goal of this study was to evaluate if the use of cysteine-containing peptide-based chelators Glu-Glu-Glu-Cys (E3C), Gly-Gly-Gly-Cys (G3C), and Gly-Gly-Gly-Ser-Cys connected via a (Gly-Gly-Gly-Ser)3-linker (designated as G3-(G3S)3C) would further improve the contrast of imaging using 99mTc-labeled derivatives of G3. The labeling of the new variants of G3 provided a radiochemical yield of over 95%. Labeled G3 variants bound specifically to human HER2-expressing cancer cell lines with affinities in the range of 1.9–5 nM. Biodistribution of [99mTc]Tc-G3-G3C, [99mTc]Tc-G3-(G3S)3C, and [99mTc]Tc-G3-E3C in mice was compared with the biodistribution of [99mTc]Tc-(HE)3-G3. It was found that the novel variants provide specific accumulation in HER2-expressing human xenografts and enable discrimination between tumors with high and low HER2 expression. However, [99mTc]Tc-(HE)3-G3 provided better contrast between tumors and the most frequent metastatic sites of HER2-expressing cancers and is therefore more suitable for clinical applications.

[1]  P. Jänne,et al.  Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. , 2021, The New England journal of medicine.

[2]  A. Schulga,et al.  Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer , 2021, The Journal of Nuclear Medicine.

[3]  Gloria S. Huang,et al.  Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. , 2021, Gynecologic oncology.

[4]  P. Jonasson,et al.  Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake , 2021, International journal of molecular sciences.

[5]  V. Tolmachev,et al.  The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. , 2021, Seminars in cancer biology.

[6]  Jiyan Liu,et al.  Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma , 2020, Clinical Cancer Research.

[7]  I. Nagtegaal,et al.  Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology , 2020, World journal of gastroenterology.

[8]  S. Al-Batran,et al.  Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction , 2020, The oncologist.

[9]  A. Schulga,et al.  On the prevention of kidney uptake of radiolabeled DARPins , 2020, EJNMMI Research.

[10]  A. Schulga,et al.  Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. , 2019, International journal of biological macromolecules.

[11]  I. Vergote,et al.  Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer , 2019, International Journal of Gynecological Cancer.

[12]  A. Schulga,et al.  Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3 , 2019, Scientific Reports.

[13]  J. Löfblom,et al.  Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 , 2019, International journal of oncology.

[14]  A. Schulga,et al.  Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. , 2019, Molecular pharmaceutics.

[15]  Jan Sundquist,et al.  Clinical landscape of cancer metastases , 2018, Cancer medicine.

[16]  E. Winer,et al.  Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  V. Tolmachev,et al.  Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors , 2018, Contrast media & molecular imaging.

[18]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[20]  D. Huo,et al.  De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype , 2017, Clinical & Experimental Metastasis.

[21]  S. Hober,et al.  Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m , 2017, Scientific Reports.

[22]  S. Kakar,et al.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K. Hemminki,et al.  Metastatic spread in patients with gastric cancer , 2016, Oncotarget.

[24]  V. Tolmachev,et al.  Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. , 2016, Molecular pharmaceutics.

[25]  W. Oyen,et al.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  H. Miyata,et al.  Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  M. Lubberink,et al.  Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT , 2016, Theranostics.

[28]  Andreas Plückthun,et al.  Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. , 2015, Annual review of pharmacology and toxicology.

[29]  A. Plückthun,et al.  Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  R. Kurzrock,et al.  HER2 aberrations in cancer: implications for therapy. , 2014, Cancer treatment reviews.

[31]  L. Abrahmsén,et al.  Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition , 2012, The Journal of Nuclear Medicine.

[32]  S. Ståhl,et al.  Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus , 2012, Tumor Biology.

[33]  Shuang Liu,et al.  99mTc-centered one-pot synthesis for preparation of 99mTc radiotracers. , 2011, Dalton transactions.

[34]  S. Hosseinimehr,et al.  Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties , 2011, The Journal of Nuclear Medicine.

[35]  L. Abrahmsén,et al.  HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. , 2010, Bioconjugate chemistry.

[36]  Andreas Plückthun,et al.  Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. , 2010, Cancer research.

[37]  A. Orlova,et al.  Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. , 2008, Cancer biotherapy & radiopharmaceuticals.

[38]  Andreas Plückthun,et al.  A designed ankyrin repeat protein evolved to picomolar affinity to Her2. , 2007, Journal of molecular biology.

[39]  Andreas Plückthun,et al.  Selection and Characterization of Her2 Binding-designed Ankyrin Repeat Proteins* , 2006, Journal of Biological Chemistry.

[40]  Andreas Plückthun,et al.  Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)–carbonyl complex , 1999, Nature Biotechnology.

[41]  V. Tolmachev,et al.  Targeted nuclear medicine. Seek and destroy , 2022, Russian Chemical Reviews.

[42]  Christine E. Edmonds,et al.  Development of Companion Diagnostics. , 2016, Seminars in nuclear medicine.

[43]  T. Butt,et al.  SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins , 2004, Journal of Structural and Functional Genomics.